Global Pellagra Market, By Type (Primary Pellagra and Secondary Pellagra), Drugs (Niacin and Niacinamide), Dosage Strength (50mg, 100mg, 250mg and 500mg), End-Users (Dermatology Clinics, Specialty Clinics, Hospitals, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Get Exclusive Sample Copy of this Report Here
Market Analysis and Insights: Global Pellagra Market
Pellagra market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.00% in the above-mentioned research forecast period. Increase in prevalence of pellagra and changing lifestyles including excess alcohol consumption among others.
Rising prevalence of gastrointestinal diseases such as Crohn’s diseases and ulcerative colitis among others and enhanced increasing awareness towards pellagra and its treatment options also boost up the market growth. Moreover, increasing research and development and rising healthcare expenditure act as opportunity for the market growth. But, sometimes adverse effect caused by niacin and niacinamide, existence of alternative aromatherapy and herbal therapies and disruption of supply chain due to impact of COVID-19 may hamper the global Pellagra market.
Pellagra is a dermatological disorder caused due to deficiency of vitamin B3 (niacin) that leads to systemic disease affecting skin, nervous system and gastrointestinal tract. The term pellagra is of Italian origin means rough skin. The most common symptoms associated with the disease includes diarrhea, dementia leading to death and dermatitis. Pellagra has been categorized into two types primary pellagra and secondary pellagra based on the niacin deficiency and body’s inability to absorb niacin. Primary pellagra is caused due to consumption of niacin lack diet that leads to niacin deficiency in body, while secondary pellagra targets the body when it loses its ability to absorb niacin that can arises due to alcoholism, carcinoid tumors, liver cirrhosis, eating disorders among others. As pellagra associated with several kinds of complications a proper diagnostic method is still unavailable, however it can be diagnosed by specifying the skin lesions demarcation and its distribution over the skin. Moreover a general procedure used for pellagra diagnosis includes measurement of urine excretion products of niacin metabolism including N1-methylnicotinamide (N1-MN) and 2-pyridone. Niacin and niacinamide are highly recommended oral therapy for pellagra treatment.
As per the Lancet publication globally alcohol consumption is the seventh leading cause of diseases and death and alcohol consumption is increasing at a rapid rate which further expected to enhance the pellagra incidence worldwide. This affected population relies of niacin supplements hence expected to provide market with the lucrative growth.
This pellagra market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Pellagra Market Scope and Market Size
Pellagra market is segmented on the basis of type, treatment, dosage, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the pellagra market is segmented into primary pellagra and secondary pellagra.
- On the basis of treatment, the pellagra market is segmented into niacin and niacinamide.
- On the basis of dosage strength, the pellagra market is segmented into 50mg, 100mg, 250mg and 500mg.
- On the basis of end-users, the pellagra market is segmented into dermatology clinics, specialty clinics, hospitals and others.
- On the basis of distribution channel, the pellagra market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Pellagra Market Country Level Analysis
Pellagra market is analysed and market size information is provided by country, type, treatment, dosage, end-users and distribution channel as referenced above.
The countries covered in the Pellagra market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the changing lifestyle with higher alcohol consumption and rising incidence of rheumatoid arthritis, Crohn's disease among other, the patient of which heavily relies on immunosuppressant drugs. Europe accounts the second largest market share due to increasing prevalence of pellagra and high consumption of maize among diet that lacks niacin. Asia-Pacific is expected to account for the largest market share over coming years for the Pellagra market due to increasing demand of effective treatment for skin diseases and presence of large number of niacin manufacturers in China and India.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Pellagra market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Pellagra Market Share Analysis
Pellagra market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Pellagra market.
The major players covered in the Pellagra market are Lonza, DSM, Bactolac Pharmaceutical, Inc., Merck KGaA, BASF SE, Foodchem International Corporation, Jubilant Life Sciences Limited, Vertellus, Western Drugs Ltd., Lasons, Bazayan & Co, Fagron, Inc., Resonance Specialties Limited among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-